{"id":"NCT00368251","sponsor":"UCB Pharma","briefTitle":"Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults","officialTitle":"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (â‰¥ 16 Years) With Genetically Ascertained Unverricht-Lundborg Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-11","primaryCompletion":"2008-01","completion":"2008-01","firstPosted":"2006-08-24","resultsPosted":"2016-04-13","lastUpdate":"2023-05-31"},"enrollment":56,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Unverricht-Lundborg Disease"],"interventions":[{"type":"OTHER","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"BRV 2.5 mg","otherNames":["ucb34714"]},{"type":"DRUG","name":"BRV 25 mg","otherNames":[]},{"type":"DRUG","name":"BRV 50 mg","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Brivaracetam 5 mg/day","type":"EXPERIMENTAL"},{"label":"Brivaracetam 150 mg/day","type":"EXPERIMENTAL"}],"summary":"The study will compare the efficacy and safety of Brivaracetam with placebo in patients with Unverricht- Lundborg Disease (ULD).","primaryOutcome":{"measure":"Percent Change From Baseline to the End of Treatment Period on the Action Myoclonus Score (Unified Myoclonus Rating Scale (UMRS) Section 4)","timeFrame":"From Baseline to End of Treatment Period (Week 14 or Early Discontinuation Visit)","effectByArm":[{"arm":"Placebo","deltaMin":17.45,"sd":null},{"arm":"Brivaracetam 5 mg/Day","deltaMin":-4.6,"sd":null},{"arm":"Brivaracetam 150 mg/Day","deltaMin":12.34,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"=0.942"},{"comp":"OG000 vs OG001","p":"=0.105"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":18,"countries":["United States","Canada","Finland","France","Israel","Russia","Serbia","Tunisia"]},"refs":{"pmids":["33461041","26666500"],"seeAlso":["https://www.briviact.com/briviact-PI.pdf?v=1479491757","http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":18},"commonTop":["Headache","Somnolence","Myoclonus","Fatigue","Nasopharyngitis"]}}